Contrykal

Contrykal Uses, Dosage, Side Effects, Food Interaction and all others data.

Contrykal is a protein-based drug that is also known as bovine pancreatic trypsin inhibitor (BPTI). Since it demonstrates the capacity to slow fibrinolysis, it has been employed to reduce bleeding during complex surgery such as heart and liver surgery. For this use, it is typically administered by injection. The goal of using of aprotinin was subsequently to minimize end-organ damage resulting from hypotension due to blood loss in surgery and to reduce the necessity for blood transfusions during surgery. Nevertheless, the drug was formally withdrawn worldwide in May of 2008 after studies confirmed that its use enhanced the risk of complications or death. The substance is consequently made available only for very restricted research use.

Contrykal is a broad spectrum protease inhibitor which modulates the systemic inflammatory response (SIR) associated with cardiopulmonary bypass (CPB) surgery. SIR results in the interrelated activation of the hemostatic, fibrinolytic, cellular and humoral inflammatory systems. Contrykal, through its inhibition of multiple mediators [e.g., kallikrein, plasmin] results in the attenuation of inflammatory responses, fibrinolysis, and thrombin generation. Contrykal inhibits pro-inflammatory cytokine release and maintains glycoprotein homeostasis. In platelets, aprotinin reduces glycoprotein loss (e.g., GpIb, GpIIb/IIIa), while in granulocytes it prevents the expression of pro-inflammatory adhesive glycoproteins (e.g., CD11b). The effects of aprotinin use in CPB involves a reduction in inflammatory response which translates into a decreased need for allogeneic blood transfusions, reduced bleeding, and decreased mediastinal re-exploration for bleeding.

Contrykal
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Contrykal
Availability	Discontinued
Generic	Aprotinin
Aprotinin Other Names	Aprotinin, Aprotinin (bovine), Aprotinin biosynthetic, Aprotinin bovine, Aprotinin concentrated solution, Aprotinina, Aprotinine, Aprotininum, Bovine aprotinin, Bovine pancreatic trypsin inhibitor, BPTI, Fibrinolysis inhibitor, Trypsin inhibitor, pancreatic basic
Related Drugs	tranexamic acid, Zoladex, goserelin, Cyklokapron, Dextran 70 6% in 5% Dextrose
Type
Formula	C₂₈₄H₄₃₂N₈₄O₇₉S₇
Weight	6511.439 Da
Groups	Approved, Investigational, Withdrawn
Therapeutic Class
Manufacturer
Available Country	Georgia, Russia
Last Updated:	September 19, 2023 at 7:00 am

Uses

Contrykal is a serine protease inhibitor used to reduce the risk for perioperative blood loss and the need for blood transfusion in high-risk patients during cardiopulmonary bypass for coronary artery bypass graft surgery.

For prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion.

Contrykal is also used to associated treatment for these conditions: Wound Healing, Maintenance of surgical hemostasis therapy

How Contrykal works

Contrykal inhibits serine proteases including trypsin, chymotrypsin and plasmin at a concentration of about 125,000 IU/mL, and kallikrein at 300,000 IU/mL. The inhibition of kallikrein inhibits formation of factor XIIa. This inhibits the intrinsic pathway of coagulation and fibrinolysis. Inhibition of plasmin also slows fibrinolysis.

Food Interaction

No interactions found.

Contrykal Disease Interaction

Moderate: hypersensitivity reaction, renal dysfunction

Elimination Route

100% (IV)

Half Life

Following this distribution phase, a plasma half-life of about 150 minutes is observed. At later time points, (i.e., beyond 5 hours after dosing) there is a terminal elimination phase with a half-life of about 10 hours.

Elimination Route

Following a single IV dose of radiolabelled aprotinin, approximately 25-40% of the radioactivity is excreted in the urine over 48 hours. After a 30 minute infusion of 1 million KIU, about 2% is excreted as unchanged drug. After a larger dose of 2 million KIU infused over 30 minutes, urinary excretion of unchanged aprotinin accounts for approximately 9% of the dose.